What is the recommended management of Graves' disease in a pregnant woman?

Management of Graves' Disease in Pregnancy

Start propylthiouracil (PTU) in the first trimester, then switch to methimazole (MMI) after 12 weeks gestation, maintaining maternal free T4 at or just above the upper limit of normal to minimize both maternal complications and fetal exposure to antithyroid drugs. 1

First-Line Medical Management

First Trimester (Weeks 0-12)

• Use PTU as first-line therapy due to the association of methimazole with specific congenital malformations (esophageal/choanal atresia, scalp abnormalities, facial bone defects) during organogenesis 1, 2
• PTU dose equivalence: 100-150 mg PTU = 10 mg MMI 1
• Monitor liver function every 3-4 weeks on PTU due to rare but severe hepatotoxicity risk 1
• Counsel patients to report new symptoms immediately (jaundice, dark urine, abdominal pain)

Second and Third Trimesters (After Week 12)

• Switch from PTU to methimazole to avoid continued PTU hepatotoxicity risk 1, 2
• When switching medications:
  • Check thyroid function after 2 weeks
  • Then monitor every 2-4 weeks 1
• Important caveat: If hyperthyroidism is well-controlled on low-dose PTU and switching may destabilize thyroid balance, continuing PTU throughout pregnancy is acceptable 2

Target Thyroid Levels

• Maintain free T4 at or just above the upper limit of the non-pregnant reference range 1
• Alternative targets: Total T4 at 1.5× upper limit of normal, or free T4 index at upper limit of normal 1
• Use the "block only" strategy (antithyroid drug alone at lowest effective dose)
• Never use block-and-replace (ATD + levothyroxine) as levothyroxine crosses the placenta poorly and increases fetal hypothyroidism risk 2

Monitoring Strategy

Maternal Monitoring

• Thyroid function tests every 2-4 weeks throughout pregnancy 1
• Adjust ATD dose to keep mother at target (slightly hyperthyroid is safer for fetus than hypothyroid)

Fetal Risk Assessment

Measure TSH receptor antibodies (TRAb) by 22 weeks gestation in ALL women with: 1

• Current Graves' disease
• History of Graves' disease treated with radioiodine or thyroidectomy before pregnancy
• Previous neonate with Graves' disease
• Previously elevated TRAb

Fetal Monitoring (If High Risk)

Perform fetal ultrasound at 18-22 weeks and repeat every 4-6 weeks if: 1

• TRAb elevated ≥2-3× normal
• Mother on antithyroid drugs

Look for signs of fetal thyroid dysfunction:

• Fetal goiter
• Fetal tachycardia (>160-170 bpm)
• Intrauterine growth restriction
• Hydrops fetalis
• Advanced bone age

Surgical Management

Consider subtotal thyroidectomy during the second trimester if: 1

1. Severe adverse reaction to both ATDs
2. Persistently high ATD doses required (>30 mg/d MMI or >450 mg/d PTU)
3. Patient non-adherence with uncontrolled hyperthyroidism

The second trimester is optimal timing to minimize anesthetic risks to the fetus.

Absolute Contraindications

• Radioactive iodine (¹³¹I) is absolutely contraindicated during pregnancy and in women who may be pregnant 1
• If inadvertently given after 12 weeks gestation, fetal thyroid destruction will occur
• Contraception should be used for 6 months after radioiodine treatment before attempting pregnancy 3

Special Considerations

Subclinical Hyperthyroidism

Do not treat subclinical hyperthyroidism in pregnancy - no evidence of benefit and potential for fetal harm 1

Hyperemesis Gravidarum

• Most cases with suppressed TSH and elevated free T4 do NOT require antithyroid drugs 1
• Consider beta-blockers (metoprolol) for symptomatic relief if significantly thyrotoxic 1
• Only treat with ATDs if confirmed Graves' disease (positive TRAb, persistent elevation beyond first trimester)

Preconception Planning

• Ideally control hyperthyroidism before conception 1
• Consider stopping ATDs in well-controlled patients on low doses before conception, with close monitoring 2, 4
• This avoids critical first-trimester drug exposure during organogenesis (weeks 6-10)

Key Pitfalls to Avoid

1. Never use block-and-replace therapy - increases fetal hypothyroidism risk
2. Don't over-treat the mother - fetal hypothyroidism from excessive ATD is worse than mild maternal hyperthyroidism
3. Don't forget TRAb testing - even women previously treated with radioiodine/surgery can have antibodies that cause fetal hyperthyroidism
4. Don't continue PTU beyond first trimester without good reason - hepatotoxicity risk persists
5. Don't assume negative TRAb means no fetal risk if mother requires ongoing ATD treatment - the drugs themselves cross the placenta

The evidence strongly supports this trimester-specific approach, balancing the teratogenic risks of methimazole in early pregnancy against the hepatotoxic risks of prolonged PTU exposure 1, 2. Recent registry data has clarified that while both drugs carry risks, the congenital malformations associated with first-trimester methimazole exposure (4.1% vs 2.1% in controls) are more severe than those with PTU 2, 4.